Skip to main content
46°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Axonics Inc
(NQ:
AXNX
)
70.98
UNCHANGED
Last Price
Updated: 4:00 PM EST, Nov 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axonics Inc
< Previous
1
2
3
4
5
6
7
Next >
5 Stocks To Watch - Tuesday, Mar. 8
March 08, 2022
Some of the stocks that may grab investor focus today.
Via
Talk Markets
5 Stocks To Watch For March 8, 2022
March 08, 2022
Some of the stocks that may grab investor focus today are: Wall Street expects Dick's Sporting Goods, Inc. (NYSE: DKS) to report quarterly earnings at $3.43 per share on...
Via
Benzinga
Analyst Ratings For Axonics
February 25, 2022
Axonics (NASDAQ:AXNX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3...
Via
Benzinga
Axonics: Q4 Earnings Insights
February 24, 2022
Axonics (NASDAQ:AXNX) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Axonics...
Via
Benzinga
Axonics® Reports Fourth Quarter and Fiscal Year 2021 Financial Results
February 24, 2022
From
Axonics, Inc.
Via
Business Wire
What 4 Analyst Ratings Have To Say About Axonics
January 07, 2022
Axonics (NASDAQ:AXNX) has observed the following analyst ratings within the...
Via
Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
Axonics® to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
February 03, 2022
From
Axonics, Inc.
Via
Business Wire
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Axonics® to Participate in SVB Leerink Virtual Healthcare Conference
February 01, 2022
From
Axonics, Inc.
Via
Business Wire
New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary Incontinence
January 25, 2022
From
Axonics, Inc.
Via
Business Wire
Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue
January 06, 2022
From
Axonics, Inc.
Via
Business Wire
Axonics® CEO Raymond W. Cohen Receives Lifetime Entrepreneurial Achievement Award by the Southern California Biomedical Council
November 30, 2021
From
Axonics, Inc.
Via
Business Wire
Axonics® Ranked the Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™
November 17, 2021
From
Axonics, Inc.
Via
Business Wire
Axonics® to Participate in Piper Sandler Virtual Healthcare Conference
November 08, 2021
From
Axonics, Inc.
Via
Business Wire
Axonics Modulation Technologies Inc (AXNX) Q3 2021 Earnings Call Transcript
November 05, 2021
AXNX earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
November 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To...
Via
Benzinga
Exposures
COVID-19
Product Safety
Axonics® Reports Third Quarter 2021 Financial Results
November 04, 2021
From
Axonics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Exposures
COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Axonics® Ranked the Fastest Growing Publicly Traded Company in Orange County
October 26, 2021
From
Axonics, Inc.
Via
Business Wire
Axonics® to Report Third Quarter 2021 Financial Results on November 4
October 07, 2021
From
Axonics, Inc.
Via
Business Wire
US Patent Office Rejects Three More Axonics' Challenge To Medtronic Patents
September 23, 2021
The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed three Medtronic plc (NYSE: MDT) patents related to its InterStim...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Axonics® Provides Additional Update on Inter Partes Review Proceedings
September 22, 2021
From
Axonics, Inc.
Via
Business Wire
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
September 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE...
Via
Benzinga
Exposures
COVID-19
Axonics® Announces Partial Decision on Inter Partes Review Proceedings
September 13, 2021
From
Axonics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
September 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
September 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
September 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:...
Via
Benzinga
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
September 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV...
Via
Benzinga
Exposures
COVID-19
Product Safety
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.